1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 97-02-12, NCT00686322
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: XYL014, NCT00708812
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Adult
Sponsor: Other
Protocol IDs: RCOG-MRC-CHORUS, EU-20350, ISRCTN74802813, NCT00075712
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HFHS 05-03, NCT00448240
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OXC4T4-302, NCT00507429
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: AMC0183, NCT00689715
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CAN-NCIC-OV21, OV.21, UCL08/0379, GEICO-0902, NCT00993655
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SINGAPORE-NCC0901, NCC0901, NCT00997906
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SWS-SAKK-22/99, EU-99028, NCT00004935
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-40101, NCT00041119
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0221, S0221, NCT00070564
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID99-146, NCT00038402
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 16
Sponsor: Other
Protocol IDs: FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: GOG-0212, NCT00108745
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11718, NCT00111007
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 119 of 2003, NCT00193739
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 64
Sponsor: Other
Protocol IDs: GBG 33, GAIN, NCT00196872
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF104383, NCT00272987
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: JCOG0505, C000000335, NCT00295789
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 to 90
Sponsor: Other
Protocol IDs: IFCT-0501, NCT00298415
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9846, B9E-IT-S376, NCT00236899
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SFC-SV001, SFC-01-0150-0001-02-CM, SFC-01-0150-001, NCT00246727
|
|
23.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR005143, NCT00338286
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CKTO-2006-04, ISRCTN14387080, CKTO-PORTEC-3, EU-20664, NCT00411138
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3104000, NCT00437307
|
